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Syk Mediates IL-17-Induced CCL20 Expression by
Targeting Act1-Dependent K63-Linked Ubiquitination
of TRAF6
Nan-Lin Wu1,2,3,4,6, Duen-Yi Huang3,5,6, Hsin-Ni Tsou3, Ying-Cing Lin3 and Wan-Wan Lin3,5
IL-17 has an important role in the immunopathogenesis of autoimmune diseases, and spleen tyrosine kinase (Syk)
has been implicated as a critical molecule in the signaling pathways of various immunoreceptors. Chemokine
(C–C motif) ligand 20 (CCL20) interacts with chemokine (C–C motif) receptor 6 to recruit IL-17-producing cells
into the skin to promote progression of psoriasis. Herein we investigate how Syk regulates IL-17 signaling to
affect CCL20 expression in primary human epidermal keratinocytes. We found that IL-17 can induce CCL20
expression and activate TAK, IKK, NF-kB, c-Jun N-terminal kinase, and Syk. Data of TAK inhibitor and Syk small
interfering RNA (siRNA) indicate Syk being an upstream molecule of TAK in IL-17-elicited signaling. The promoter
activity assay combined with site-directed mutagenesis showed that IL-17-elicited CCL20 upregulation is
depending on the Syk-mediated NF-kB pathway. Immunoprecipitation also indicated the interaction of Syk with
signal molecules of IL-17R, such as TRAF6 and Act1, under IL-17A stimulation. However, the essential signaling
events including TRAF6 interaction with Act1 and TRAF6 polyubiquitination under IL-17A stimulation were
diminished by Syk siRNA and pharmacologically inhibiting Syk. Taken together, we identify Syk as an upstream
signaling molecule in IL-17A-induced Act1-TRAF6 interaction in keratinocytes, and inhibition of Syk can attenuate
CCL20 production, which highlights Syk as a potential therapeutic target for inflammatory skin diseases such as
psoriasis.
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INTRODUCTION
IL-17A is the most characterized cytokine among the six
members of IL-17 family (Gaffen, 2009). IL-17A is mainly
produced by Th17 cells and involved in autoimmune diseases
(Chang and Dong, 2011; Zepp et al., 2011). So far, five
members of the IL-17R family have been identified, and a
cytosolic SEF/IL-17R (SEFIR) domain is conserved in IL-17R.
Upon IL-17 stimulation, IL-17RA and IL-17RC form a
heterdimeric complex to recruit Act1 through the SEFIR
domain. Act1 then recruits TRAF6 to the receptor complex
through its TRAF-binding domain. In addition, Act1 is a U-box
like E3 ubiquitin ligase that can mediate K63-linked polyu-
biquitination of TRAF6, a critical step for the IL-17-induced
signaling pathway (Liu et al., 2009). The ubiquitinated TRAF6
then leads to the activation of TAK1-IKK and TAK1-mitogen-
activated protein kinase complexes, which are the upstream
signaling of NF-kB and AP-1 (Chang and Dong, 2011; Sonder
et al., 2011; Zepp et al., 2011). Recently, deubiquitinases
USP2 and A20 were identified to mediate feedback inhibition
of IL-17R signaling (Liu et al., 2009; Zhong et al., 2012; Garg
et al., 2013).
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine
kinase and regulates diverse biological functions. Syk is widely
expressed in hematopoietic cells and mediates the innate and
adaptive immune responses. Nevertheless, Syk is also
expressed in epithelial cells, fibroblasts, osteoclasts, and
synoviocytes (Mocsai et al., 2010; Riccaboni et al., 2010).
The most well-known function of Syk is its important roles in
immunoreceptor activation. When ligands (e.g., major
histocompatibility complex (MHC), antigens, IgE) attach to
immunoreceptors (such as BCR, FcgRI), the Src family
kinases Lyn and/or Fyn can phosphorylate the
immunoreceptor tyrosine–based activation motif of immunor-
eceptors or their associated adaptors, in turn recruiting
Syk through its N-terminal SH2 domains binding to the
phosphorylated immunoreceptor tyrosine–based activation
motif for Syk activation (Turner et al., 2000; Tohyama and
Yamamura, 2009; Mocsai et al., 2010; de Castro, 2011).
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Besides activation by receptors whose activation relies on
immunoreceptor tyrosine–based activation motif, Syk also can
be activated by integrins (Hamerman et al., 2009; Mocsai
et al., 2010), toll-like receptors (Lee et al., 2009; Zanoni et al.,
2011; Lu et al., 2012; Lin et al., 2013), and tumor necrosis
factor (TNF) receptor. Syk activation has an essential role in
TNF-induced activation of mitogen-activated protein kinases,
NF-kB, and apoptosis in Jurkat T cells (Takada and Aggarwal,
2004), matrix metalloproteinase generation in synovio-
cytes (Chae et al., 2006), and nitric oxide production in
airway epithelial cells (Takada and Aggarwal, 2004; Ulanova
et al., 2006).
As IL-17A and Syk have important roles in the pathogenesis
of various autoimmune diseases, we wonder whether Syk is
involved in the signaling of IL-17R and participates to regulate
gene expression. To this end, we used primary human
keratinocytes as a cell model to address the role of Syk in
IL-17A-induced chemokine (C–C motif) ligand 20 (CCL20)
expression. As reported, CCL20 is the most inductive chemo-
kine during IL-17A stimulation in keratinocytes and can
interact with chemokine (C–C motif) receptor 6 to recruit
more IL-17A-producing cells into the skin, which mediates the
pathogenesis of several skin diseases such as psoriasis
(Nograles et al., 2008; Harper et al., 2009; Becher and
Pantelyushin, 2012). Our data in this study provide the
evidence that Syk is a downstream signaling molecule of IL-
17R in regulating TRAF6 polyubiquitination and CCL20 gene
expression and suggest that inhibition of Syk function may be
a therapeutic way to treat IL-17A-related diseases such as
psoriasis.
RESULTS
IL-17A increases CCL20 protein and mRNA expression in
keratinocytes
In primary keratinocytes, we found that IL-17A treatment can
increase the protein expression of CCL20 in concentration-
and time-dependent manners (Figure 1a and b). Confirming
that this effect of IL-17A is specific, and not due to any
contamination in the cytokine preparation, we found that
IL-17A-induced soluble CCL20 release can be abolished by
the IL-17A-neutralizing antibody (Figure 1c). In parallel,
CCL20 mRNA levels were concomitantly increased along
with IL-17A concentration elevated (Figure 1d). In addition,
IL-17A-induced CCL20 mRNA expression was markedly
increased at 3 hour incubation. Afterward, it was gradually
decreased but still remained at a level of 10-fold higher than
control after treatment for 9 hours (Figure 1e).
Involvement of Syk in IL-17R-mediated signaling pathways
As shown in Figure 2a, IL-17A can induce Syk activation.
Moreover, IL-17A treatment led to the phosphorylation of
TAK1, IKK, and IkBa, which are pivotal components in the
upstream signaling pathway for NF-kB activation. In addition,
IL-17A also induced phosphorylation of c-Jun N-terminal
kinase (JNK), p38, and MKK4 but mildly suppressed
extracellular signal–regulated kinase (ERK) activity. Notably,
Syk small interfering RNA (siRNA) treatment significantly
decreased IL-17A-induced TAK1, IKK, IkBa, JNK, and MKK4
phosphorylation, indicating Syk as the upstream molecule in
IL-17R-mediated signaling pathways.
Next, we further confirmed the bifurcated signaling path-
ways propagated by IL-17R––i.e., TAK1-IKK-IkBa and TAK1-
MKK4-JNK. To explore the signaling, we used TAK1 inhibitor
(TAKI), (5Z)-7-oxozeaenol, which can inhibit both the kinase
and the ATPase activity of TAK1 by forming a covalent complex
with TAK1 (Wu et al., 2013a). As shown in Figure 2b, TAKI as
expected can suppress IL-17A-induced IKK, IkBa, JNK, and
p38 but not Syk phosphorylation. On the other hand, IKK
inhibitor BMS-345541, which inhibits IKK-mediated signaling
through acting on the allosteric sites on IKK1 and IKK2, can
reduce IkBa phosphorylation but failed to reduce IL-17A-
induced TAK1, IKK, and JNK phosphorylation (Figure 2c, right
panel). Neither JNK inhibitor SP600125 inhibited TAK1, IKK,
and IkBa phosphorylation (Figure 2c, left panel). These results
suggest that Syk might be a prerequisite molecule upstream
TAK1 in IL-17R signaling.
Syk/NF-jB signaling participates in IL-17A-induced CCL20
expression
To explore pathways involved in the IL-17-induced CCL20
expression by using different kinase inhibitors, we confirmed
that these inhibitors including BAY61-3606, BMS-345541,
SP600125, TAKI, and siRNA reagents mildly affect the survival
of keratinocytes within 12 hours (Figure 3a). To understand
whether Syk might participate in IL-17A-induced CCL20
expression, we treated cells with Syk inhibitor. We found that
BAY61-3606 strikingly inhibited IL-17A-induced CCL20 pro-
duction, and so did BMS-345541. In contrast, SP600125 had
no inhibitory effect on IL-17A-induced CCL20 expression
(Figure 3b). As expected, BAY61-3606 significantly suppressed
CCL20 mRNA expression in response to IL-17A (Figure 3c).
siSyk transfection also exerted significant inhibition of IL-17A-
induced CCL20 secretion and gene expression (Figure 3d and
e). Although the difference in Figure 3d is relatively less
obvious when the data are presented in the fold of induction
ratio compared with that of net protein amount, the difference
is still statistically significant. Taken together, these results
indicate that Syk acts as a positive regulator in IL-17A-
mediated CCL20 gene expression.
NF-kB is an important regulator of chemokine gene expres-
sion (Ghosh et al., 1998; Awane et al., 1999; Karin and
Delhase, 2000; Richmond, 2002). We wondered whether
IL-17A exerts NF-kB activation via a Syk-dependent manner.
As shown in Figure 4a, IL-17A indeed enhanced NF-kB
luciferase activity. With co-treatment with BAY61-3606 or
knockdown of Syk, IL-17A-induced NF-kB induction was
inhibited. Next, we dissected whether NF-kB and JNK-depen-
dent AP-1 are involved in IL-17A-mediated CCL20 gene
induction. To this end, we generated the NF-kB and
AP-1 site-directed mutation constructs of CCL20 promoter
with a 3 bp substitution (Figure 4b). As shown in Figure 4c,
CCL20 reporter activity displayed a fivefold increase under
IL-17A stimulation. Mutation of the NF-kB binding site
obviously abolished luciferase activity in response to IL-17A,
whereas AP-1 mutation kept the IL-17A response nearly
unchanged. Moreover, treating cells either with BAY61-3606
N-L Wu et al.
Syk Is a Signaling Molecule of IL-17R
www.jidonline.org 491
or siSyk reduced IL-17A-induced CCL20 luciferase activity
(Figure 4c). Thus, we suggest that Syk-mediated NF-kB but not
AP-1 is crucial for CCL20 gene expression upon IL-17A
stimulation.
Syk mediates Act1-TRAF6 complex formation and TRAF6
polyubiquitination
After observing that Syk is an upstream molecule for TAK1-
dependent signals, we clarified its interaction to Act1 and
TRAF6. Results of co-immunoprecipitation with Syk antibody
followed by immunobloting analysis revealed that after IL-17A
treatment association of Syk with TRAF6, Act1, and IL-17R
was obviously enhanced (Figure 5a). Conversely, when we
immunoprecipitated Act1, we also found that Act1 can bind to
Syk and IL-17R (Figure 5b). These data suggest that Syk may
form a complex with TRAF6 and Act1, and this signalosome
can be recruited to IL-17R upon IL-17A stimulation.
To further understand the impact of Syk in the IL-17R-
mediated upstream signaling pathway, knockdown of Syk was
performed. As shown in Figure 6a, Syk siRNA transfection
strikingly attenuated the interaction between TRAF6 and Act1,
suggesting the essential role of Syk in the proximal signalo-
some complex formation. As K63 ubiquitination of TRAF6
mediated by Act1 but negatively regulated by USP25 and A20
is critical in IL-17-induced activation of NF-kB (Liu et al.,
2009; Zhong et al., 2012; Garg et al., 2013), we next tried to
understand the role of Syk in TRAF6 ubiquitination. Our
results revealed that IL-17 treatment can increase the TRAF6
ubiquitination, and this effect was reduced by BAY61-3606
and siRNA silencing of Syk (Figure 6b).
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Figure 1. IL-17A increases chemokine (C–C motif) ligand 20 (CCL20) expression in keratinocytes. (a) Keratinocytes were treated with the indicated
concentrations of IL-17A for 24 hours. Then, the media were collected and measured with the CCL20 ELISA kit. Similar experimental procedures were conducted
at 100 ng ml–1 of IL-17A (b) or 5mg ml–1 control IgG (IgG), IL-17A-neutralizing antibody (Ab), and IL-17A for 12 hours (c). (d) Keratinocytes were treated with IL-
17A for 3 hours, followed by quantitative reverse transcriptase in real time analysis of CCL20 mRNA. (e) Similar experimental procedures were conducted at
100 ng ml–1 of IL-17A for the indicated time. Values were normalized to b-actin and expressed relative to the control group. Data were the mean±SEM from three
independent experiments. *Po0.05, indicating significant effects of IL-17A as compared with control or IL-17A neutralizing Ab as compared with control IgG.
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DISCUSSION
Th17 cells have been implicated in the pathogenesis of various
inflammatory autoimmune disorders (Chiricozzi et al., 2011;
Zhu and Qian, 2012), and IL-17A is considered as the
therapeutic target in psoriasis (Chiu et al., 2012; Waisman,
2012). According to previous research, IL-17A leads to the
induction of various pro-inflammatory genes in keratinocytes
(Nograles et al., 2008; Onishi and Gaffen, 2010; Chiricozzi
et al., 2011). In this study, we particularly focus on IL-17A-
induced CCL20 chemokine, which has an important role in
psoriatic skin lesions (Homey et al., 2000). CCL20 can interact
with its receptor chemokine (C–C motif) receptor 6 to recruit
IL-17A-producing cells into the skin (Becher and Pantelyushin,
2012). It has been demonstrated that NF-kB and mitogen-
activated protein kinase signaling pathways were involved in
IL-17A stimulation. However, little is known about whether
Syk participates in IL-17R signaling or not. Notably, recent
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Figure 2. Role of spleen tyrosine kinase (Syk) in IL-17A-mediated signaling pathways. (a) Keratinocytes were transfected with siSyk or control small interfering
RNA (siRNA; 20 nM) for 48 hours, and then cells were treated with IL-17A (100 ng ml–1) for the indicated time periods. (b, c) Keratinocytes were pretreated with
TAK1 inhibitor (TAKI; 1mM) (b), BMS-345541 (10mM), or SP600125 (2mM) (c) for 30 minutes, and then stimulated with IL-17A (100 ng ml–1) for the indicated time.
Total cell lysates were subjected to SDS-PAGE followed by immunoblotting for Syk, IKK, TAK1, IkBa, c-Jun N-terminal kinase (JNK), extracellular signal–regulated
kinase (ERK), p38, and MKK4.
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studies have raised attention on Syk as a promising therapeutic
target, and many clinical trials for Syk inhibitors in several
autoimmune diseases such as rheumatoid arthritis, asthma, and
allergic rhinitis are undergoing (Meltzer et al., 2005; Mocsai
et al., 2010; Pamuk and Tsokos, 2010; Riccaboni et al., 2010)
IL-17R-proximal signaling complex (IL-17R-Act1-TRAF6) is
essential for IL-17A-mediated NF-kB activation. Here using
pharmacological and genetic approaches we demonstrated
that Syk is a mediator for the complex formation. In addition,
IL-17A can induce Syk phosphorylation and trigger down-
stream TAK1, IKK, and IkBa phosphorylation. In contrast, TAK
inhibitor failed to alter Syk activation. All these results indicate
that Syk might be the upstream molecule of TAK and has a
critical role in IL-17R signaling.
NF-kB is an important regulator of the immune system and
inflammatory diseases and involved in chemokine gene
transcription. Here we showed that IL-17A-mediated CCL20
production results from the activation of NF-kB. First, we
found kB activity is upregulated upon IL-17A stimulation.
Second, IKK inhibitor BMS-345541 exerts an inhibitory effect
on IL-17A-induced CCL20 expression. Finally, IL-17A-induced
CCL20 promoter activation is abrogated when kB-binding site
in CCL20 promoter is mutated. Given that Syk is the upstream
signal of TAK1, as expected, pretreating keratinocytes with Syk
inhibitor BAY61-3606 or knockdown of Syk by siRNA reveals
a compelling suppression of IL-17A-induced CCL20 expres-
sion in both gene and protein levels. Accordingly, pretreat-
ment with BAY61-3606 or knockdown of Syk diminished
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Figure 3. Role of spleen tyrosine kinase (Syk) in IL-17A-induced chemokine (C–C motif) ligand 20 (CCL20) expression. (a, b) Keratinocytes were pretreated with
inhibitors for 30 minutes or transfected with siSyk or control small interfering RNA (siRNA) for 48 hours, and then with IL-17A (100 ng ml–1) for 12 hours. Cell
survival rates were determined by 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide. (c) Keratinocytes were pretreated with BAY61-3606 (10mM) for
30 minutes, and then with IL-17A. (d, e) Keratinocytes were transfected with siSyk or control siRNA for 48 hours, and then with IL-17A treatment. CCL20 secretion
was assessed by ELISA (b, d), and gene expression was validated by quantitative reverse transcriptase in real time (c, e). Data showed results from three
independent experiments. *Po0.05, indicating significant inhibition of CCL20 expression by inhibitors or siSyk. (d) The numbers in parenthesis represent the fold
increase as compared with individual control groups.
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IL-17A-induced NF-kB activation and CCL20 promoter activ-
ity. Even though previous study has demonstrated that inhibi-
tion of Syk can reduce TNF-induced NF-kB activation and
NF-kB-mediated gene expression through suppression of IkBa
and p65 phosphorylation (Ashikawa et al., 2002), no further
information shows the relationship between Syk and the IKK/
NF-kB pathway. Our current data that IL-17A-induced CCL20
production depends on Syk-mediated NF-kB signaling
pathway confer an alternative but important function of Syk
in regulating inflammatory response.
Nevertheless, we also observed the phosphorylation of JNK
in IL-17R signaling in keratinocytes, indicating that AP-1
involves in IL-17R-mediated downstream target genes. To
clarify this suspicion, we generated the AP-1 site-directed
mutagenesis of CCL20 promoter and found that only CCL20
promoter construct with NF-kB mutation strikingly abolishes
IL-17A-induced CCL20 luciferase activity. Previously, actions
of many CCL20 inducers such as TNF-a, hypoxia, desferriox-
amine, HTLV-I (human T-cell leukemia virus type-I), LMP-1
(latent membrane protein 1), and KSHV (Kaposi sarcoma–
associated herpesvirus) highlight the importance of NF-kB as
well (Imaizumi et al., 2002; Sugita et al., 2002; Okudaira
et al., 2006; Battaglia et al., 2008; Varesio et al., 2010). In
addition, two reports also exclude the requirement of AP-1 for
CCL20 expression (Battaglia et al., 2008; Kanda et al., 2009).
Taken together, our results demonstrate that IL-17A-induced
CCL20 is dependent on NF-kB rather than AP-1 activation.
As TAK is considered as an upstream signal molecule for
NF-kB and mitogen-activated protein kinase activation trig-
gered by a variety of pro-inflammatory stimuli such as IL-1b,
TNF-a, LPS, and IL-17 (Irie et al., 2000; Sato et al., 2005), it is
not surprising to observe the phosphorylation of TAK1, IKK,
JNK, and p38 in IL-17A-stimulated keratinocytes in our study.
Nevertheless, the ERK was mildly suppressed. As reported,
activation of ERK and p38 is induced by IL-17A stimulation
in human bronchial epithelial cells, colonic myofibro-
blasts, airway smooth muscle cells, and lung microvascular
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endothelial cells (Hata et al., 2002; Laan et al., 2003; Prause
et al., 2003). The study by Kanda et al. (2009) using human
keratinocyte as a model also showed JNK and ERK
phosphorylation under IL-17A treatment. We speculate that
the different findings for ERK activation might be due to the
cell types and/or cell status. In the study by Kanda et al.
(2009), human neonatal foreskin keratinocytes were used,
whereas we used human foreskin keratinocytes from adults.
It has been reported that Act1 interacts with other IL-17A
signaling components such as IL-17R, TAK1, and TRAF6 in
human primary fibroblasts (Qian et al., 2007; Liu et al., 2009).
Although Syk is activated by some immune receptors, and
thereby orchestrates various cellular processes such as
cytokines production, bone resorption, and phagocytosis
(Riccaboni et al., 2010), up to date the engagement of Syk
with IL-17R signaling has never been addressed. In this study,
we clearly observed that IL-17A can promote Syk to form a
complex with TRAF6 and Act1. In addition, we did not detect
the expression of TAK1 in the protein complexes immuno-
precipitated by Syk or Act1 antibody (data not shown).
Combining with previous data that TAK1 is associated with
TRAF6 after IL-17R activation (Takaesu et al., 2000; Qian
et al., 2007; Walsh et al., 2008), we speculate that Syk is
recruited to the complex of Act1/TRAF6 rather than TRAF6/
TAK1 in IL-17R signaling. This suggestion is different from our
previous findings on TLRs signaling in murine macrophages
where activated Syk is recruited to TRAF6/TAK1 (Lin et al.,
2013). Therefore, we suggest that Syk might be a common
regulator of TRAF6-dependent signaling and cellular function,
whereas its action mode is cell type and stimuli dependent.
Moreover, the most importantly, evidence shown in this study
to support the crucial role of Syk in Act1/TRAF6 complex
formation is the decreased interaction between TRAF6 and
Act1 and decreased K63 polyubiquitination of TRAF6 in
keratinocytes with lower Syk expression. These results
indicate that Syk has a critical role in positively mediating
TRAF6 signaling and cellular response of IL-17R in keratino-
cytes. The molecular mechanisms in details how Syk regulates
K63 polyubiquitination of TRAF6 linking to its phos-
phorylation targets need further investigation in the future.
In summary, we unmask a crucial upstream signaling
molecule in IL-17R. We demonstrate that IL-17A elicits
CCL20 gene expression and protein secretion in human
keratinocytes via a Syk-dependent NF-kB mechanism. Upon
IL-17A stimulation, Syk forms a complex with Act1/TRAF6 and
mediates Act1-TRAF6 interaction and TRAF6 polyubiquitina-
tion. These data not only provide an insight into the molecular
signaling of IL-17R but also disclose Syk as a promising
therapeutic target in psoriasis.
MATERIALS AND METHODS
Reagent
Antibodies directed against IKKa/b (sc-7607), Syk (sc-1240), TAK1
(sc-7162), IkBa (sc-371), JNK1 (sc-474), ERK2 (sc-154), p38 (sc-7149),
TRAF6 (sc-7221), Act1 (sc-11444), IL-17R (sc-30175), and horse-
radish peroxidase-coupled second antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibodies for phosphorylated IKKa/
b (Ser176/177, #2078), Syk (Tyr525/526, #2711), TAK1 (Thr184/187,
#4508), IkBa (Ser32, #2859), MKK4 (Ser257/Thr276, #9156), JNK
(Thr183/Tyr185, #9251), ERK (Thr202/Tyr204, #9101), p38 (Thr180/
Tyr182, #9211), and total MKK4 (#9152) were from Cell Signaling
Technology (Beverly, MA). Antibody against b-actin (MAB1501) was
from Upstate Biotechnology (Charlottesville, VA). Antibody against
K63-specific ubiquitin (#14-6077-82) was from Enzo Life Sciences
(Farmingdale, NY). Control IgG and IL-17-neutralizing antibody (AF-
317-NA) were from R&D Systems (Minneapolis, MN). The enhanced
chemiluminescence reagent was from Perkin Elmer (Wellesley, MA).
The recombinant endothelial growth factor, protease, and protease
inhibitor cocktails were from Sigma-Aldrich (Saint Louis, MO). Soluble
human recombinant IL-17A was from PeproTech (Rocky Hill, NJ).
BAY61-3606 and BMS-345541 were from Calbiochem (San Diego,
CA). The JNK inhibitor SP600125 was from Tocris Cookson (Ellisvillw,
MO). The TAK inhibitor was from Bioaustralis (Smithfield, Australia).
The RNA-Bee isolation reagent was from Tel-Test (Friendwood, TX).
The FastStart SYBR Green Master was from Roche Applied Science
(Nutley, NJ). The Keratinocyte-serum free medium and bovine
pituitary extract were from Gibco BRL/Invitrogen (Carlsbad, CA).
Cell culture
Normal human epidermal keratinocytes were obtained from normal
adult human foreskin and were cultured as we previously described
(Wu et al., 2013b). The second to fourth passage cells were used in
experiments. The experiments were conducted according to the
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Figure 6. Syk mediates Act1-TRAF6 association and TRAF6 K63
ubiquitination. (a) Keratinocytes were transfected with siSyk or control small
interfering RNA (siRNA; 20 nM) for 48 hours, and then treated with IL-17A
(100 ng ml–1) at the indicated time. Total cell lysates were immunoprecipitated
with anti-TRAF6, anti-Act1, or IgG, followed by protein analysis in the
immunoprecipitates. (b) Keratinocytes were treated with BAY61-3606 (10mM)
for 30 minutes or siSyk for 48 hours, followed by IL-17A stimulation for the
indicated periods. Then, cell lysates were immunoprecipitated with TRAF6
antibody followed by determining K63 polyubiquitination.
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Declaration of Helsinki Principles and approved by the ethical
committee of Mackay Memorial Hospital (institutional review board
code: 10MMHIS179). Written consent was obtained from each donor
before experiments were performed.
Immunoblotting analysis
Protein expression was determined in cell lysates by electrophoresis
and immunobloting as we previously described (Wu et al., 2013b).
Immunoprecipitation
For immunoprecipitation, cells were washed with ice-cold phos-
phate-buffered saline and then lysed in 1 ml RIPA lysis buffer (50 mM
Tris-HCl, pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1%
deoxycholate, 2 mM EDTA, 2 mM NaF, 2 mM b-glycerolphosphate,
2 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and protease
inhibitor cocktails) and centrifuged at 12,500 rpm at 4 1C for 10 min-
utes. The supernatant was collected and pre-cleaned with 0.4mg
normal IgG and 10ml protein A-agarose beads at 4 1C for 1 hour. After
centrifugation, supernatant was incubated with specific antibody at
4 1C overnight, and then 10ml protein A-agarose beads were added
for another 1 hour. The immunocomplexes were washed one time
with cold RIPA buffer containing 150 mM NaCl, three times with RIPA
buffer containing 300 mM NaCl, and finally RIPA buffer containing
150 mM NaCl again. 1 SDS gel-loading buffer was added to the pre-
cipitated complexes, and heat the samples at 95 1C for 5 minutes. After
spinning down the samples, loading the supernatants onto the SDS-
PAGE, immunoblotting analysis was performed as described above.
Real-time RT-PCR
The expression of human CCL20 mRNA was determined by real-time
RT-PCR analysis. The specific primers for human CCL20 were
forward primer 50-TACTCCACCTCTGCGGCGAATCAGAA-30 and
reverse primer 50-GTGAAACCTCCAACCCCAGCAAGGTT-30. The
specific primers for b-actin were forward primer 50-CGGGGACCTG
ACTGACTACC-30 and reverse primer 50-AGGAAGGCTGGAAGA
GTGC-30. The experiment and data analysis were conducted as we
previously reported (Lin et al., 2013).
3-(4,5-Cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
assay
Keratinocytes were treated with indicated drugs for 12 hours, and
then the cell viability was measured by the 3-(4,5-cimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide assay as described previously
(Wu et al., 2011).
ELISA
Primary human keratinocytes were stimulated with indicated agents.
Culture supernatants were harvested and centrifuged at 1,000 rpm to
remove cell debris. The concentration of CCL20 in the supernatants
was measured by the DuoSet ELISA development kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s instructions.
RNA interference
Human siSyk (Cat no. J-003176-13-0020) and scramble nonspecific
siRNA were purchased from Dharmacon Research (Lafayette, CO).
Primary human keratinocytes were transfected with 100 nM siRNA by
DharmaFECT Transfection Reagents (Dharmacon Research) at 50%
confluence following the manufacturer’s instruction. After siRNA
transfection for 48 hours, cells were treated with indicated drugs
and then harvested for analysis.
Transient transfection and luciferase assay
The NF-kB reporter plasmid containing three kB binding sites (pGL2-
ELMA-luciferase) was provided by Dr S.-L, Hsieh (Yang-Ming Uni-
versity, Taipei, Taiwan). Human CCL20 promoter-luciferase reporter
construct was a gift from Dr Reen Wu (University of California, Davis,
USA). Following the commercial standard protocol, primary human
keratinocytes were transfected with NF-kB or human CCL20 reporter
plasmids of wild type, kB, or AP-1 mutation, together with
b-galactosidase expression vector (pSVlacZ) by using Lipofectamine
2000 Transfection reagent (Invitrogen) for 24 hours. After the indi-
cated reagent treatment, cells were lysed in reporter lysis buffer
(Promega, Madison, WI). Subsequently, the lysates were reacted with
commercial luciferase substrate provided in the luciferase assay
system kit (Promega) and were assayed by microplate luminometer
(Packard, Meriden, CT). Luciferase activity values were normalized to
transfection efficiency monitored by b-galactosidase expression and
presented as the percentages of luciferase activity of the control group.
Site-directed mutagenesis
Point mutation of NF-kB and AP-1 binding sites in human CCL20
promoter was achieved by using the QuikChange Site-Directed
Mutagenesis Kit from Agilent Technologies (Santa Clara, CA). Primers
for mutated human CCL20 promoter were designed as follows:
CCL20kB mut-F: 50-GCCAGTTGATCAATGGGGAAAAAAACATGTG
GCAACACG-30; CCL20kB mut-R: 50-CGTGTTGCCACATGTTTTTTT
CCCCATTGATCAACTGGCC-30; CCL20 AP-1 mut-F: 50-TCCTTGCG
GGTTTTTTTTATGAGGAAATCATGGGGCCAGTTGATC-30; CCL20
AP-1 mut-R: 50-GATCAACTGGCCCCATGATTTCCTCATAAAAAAAA
CCCGCAAGGA-30.
Statistical evaluation
Values were expressed as the mean±SEM of at least three indepen-
dent experiments, which were performed in duplicate. Analysis
of variance was used to assess the statistical significance of
the differences, and a P-valueo0.05 was considered statistically
significant.
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